Skip to main content

Table 2 Clinical factors associated with 8-week overall survival

From: Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study

 

Univariable analysis

Multivariable analysis*

HR (95% CI)

p

HR (95% CI)

p

Clinical factors

    

 Age

1.03 (1.00–1.05)

0.020

1.00 (0.98–1.03)

0.714

 Male sex

0.68 (0.34–1.36)

0.272

  

 Symptom duration, days

1.00 (0.99–1.01)

0.450

  

 Steroid use prior to the treatment

0.84 (0.39–1.81)

0.653

  

 Baseline MELD

1.09 (1.04–1.14)

< 0.001

1.09 (1.03–1.16)

0.005

 Baseline GFR, mL/min/1.73 m2†

0.99 (0.99–1.00)

0.064

1.00 (1.00–1.01)

0.623

 Baseline H-score

1.00 (0.99–1.01)

0.524

  

 Baseline fibrinogen, mg/dL

1.00 (0.99–1.00)

0.144

  

Underlying cause

    

 Rheumatic disease

0.93 (0.38–2.25)

0.864

  

 Malignancy

0.49 (0.20–1.20)

0.119

  

 Infection

0.82 (0.35–1.88)

0.632

  

 Idiopathic

2.21 (1.09–4.49)

0.028

2.44 (1.11–5.36)

0.027

Treatment at baseline

    

 HLH-2004 regimen

0.69 (0.35–1.39)

0.302

  

 Chemotherapy

0.36 (0.09–1.52)

0.166

  

 Other immunosuppressant

0.54 (0.13–2.26)

0.400

  

 Steroid only

3.21 (1.30–7.95)

0.012

2.85 (0.98–8.30)

0.056

 Tocilizumab

2.92 (1.25–6.82)

0.013

5.55 (2.13–14.49)

< 0.001

  1. Bold text indicates a statistically significant difference with a p-value less than 0.05
  2. *Adjusted for clinical factors with relevant association (P < 0.1) in univariable analysis
  3. The variable was included in the model as a continuous variable
  4. GFR, glomerular filtration rate; HLH, hemophagocytic lymphohistiocytosis; MELD, Model For End-Stage Liver Disease